Tirzepatide is a groundbreaking, FDA-approved injectable medication offering a powerful new approach to chronic weight management and the treatment of Type 2 Diabetes Mellitus (T2DM). It is a first-in-class molecule known as a dual GIP and GLP-1 receptor agonist.
As a trusted medical provider, we are committed to providing you with clear, science-backed information on this innovative treatment.
Tirzepatide
Plans as low as $199/month
Tirzepatide is often called a "twincretin" because it simultaneously mimics the effects of two natural gut hormones, Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1). This dual-action mechanism is what sets it apart, providing superior metabolic and weight loss benefits:
-
Enhanced Appetite Control (GLP-1 & GIP): It influences the hunger centers in the brain, significantly reducing appetite and increasing the feeling of satiety (fullness) after eating.
-
Insulin Secretion and Blood Sugar Control (GLP-1 & GIP): It stimulates the pancreas to release insulin only when blood sugar levels are high (glucose-dependent).
-
Reduced Glucagon (GLP-1): It suppresses the release of glucagon, a hormone that raises blood sugar, leading to improved glycemic control.
-
Slower Digestion (GLP-1): Like single-action GLP-1s, it slows gastric emptying, which contributes to feeling fuller for longer and helps prevent blood sugar spikes after meals.
-
Improved Adipose Tissue Function (GIP): GIP agonism is also thought to improve the function of white adipose (fat) tissue and enhance insulin sensitivity.